Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
47 studies found for:    phenylbutyrate
Show Display Options
Rank Status Study
21 Completed Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors
Condition: Brain Tumor
Intervention: Drug: Phenylbutyrate
22 Unknown  Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer
Conditions: Gastric Cancer;   Head and Neck Cancer;   Lymphoma;   Lymphoproliferative Disorder
Interventions: Drug: oral sodium phenylbutyrate;   Drug: valganciclovir;   Genetic: polymerase chain reaction;   Genetic: protein expression analysis;   Procedure: biopsy
23 Not yet recruiting A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders (UCDs)
Condition: Urea Cycle Disorder
Intervention: Drug: RAVICTI
24 Completed
Has Results
Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)
Condition: Urea Cycle Disorders
Interventions: Drug: HPN-100;   Drug: Buphenyl (NaPBA)
25 Completed Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: azacitidine;   Drug: sodium phenylbutyrate
26 Completed Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate Cancer
Conditions: Leukemia;   Lung Cancer;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Prostate Cancer
Interventions: Drug: azacitidine;   Drug: sodium phenylbutyrate
27 Completed Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Biological: sargramostim;   Drug: dexamethasone;   Drug: oral sodium phenylbutyrate
28 Completed Phase I and Pharmacokinetic Trial of Phenylbutyrate Given as a Continuous Infusion in Pediatric Patients With Refractory Malignancy
Conditions: Brain Neoplasms;   Neuroblastoma
Intervention: Drug: phenylbutyrate
29 Completed Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment
Conditions: Lymphoma;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: azacitidine;   Drug: sodium phenylbutyrate
30 Completed 5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
Condition: Beta Thalassemia
Intervention: Drug: 5-Azacytidine
31 No longer available Buphenyl Therapy for Byler's Disease
Condition: Byler Disease
Intervention: Drug: Buphenyl
32 Recruiting Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation
Condition: Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
Intervention: Drug: Ravicti
33 No longer available Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease
Condition: Byler Disease
Intervention: Drug: Glycerol phenylbutyrate
34 Completed Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: sodium phenylbutyrate;   Drug: tretinoin
35 Terminated Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
Condition: Thalassemia Major
Interventions: Drug: azacitidine;   Drug: phenylbutyrate
36 Completed Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders
Condition: Amino Acid Metabolism, Inborn Errors
Interventions: Drug: Sodium Benzoate;   Drug: Sodium Phenylacetate;   Drug: Sodium Phenylbutyrate;   Behavioral: Dietary Intervention
37 Completed Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
Condition: Urea Cycle Disorders
Intervention: Drug: HPN-100
38 Active, not recruiting Effect of Endoplasmic Reticulum Stress on Metabolic Function
Conditions: Insulin Resistance;   Diabetes;   Obesity
Interventions: Drug: tauroursodeoxycholic acid;   Other: placebo;   Drug: sodium phenylbutyrate
39 Completed A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group
Conditions: Hepatic Encephalopathy;   Urea Cycle Disorders
Intervention: Drug: HPN-100
40 Active, not recruiting To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
Condition: Urea Cycle Disorders
Intervention: Drug: HPN-100

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-47) Show next page of results    Last Page
Indicates status has not been verified in more than two years